{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:05Z","timestamp":1788966065327,"version":"build-2803163510"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0184380","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T17:38:34Z","timestamp":1505237914000},"page":"e0184380","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-2752","authenticated-orcid":true,"given":"Mei-Yi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Der-Cherng","family":"Tarng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Ho","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,9,12]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"Heart Disease and Stroke Statistics\u20142011 Update: A Report From the American Heart Association","volume":"123","author":"VL Roger","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/j.ajkd.2011.07.023","article-title":"Decongestive treatment of acute decompensated heart failure: cardiorenal implications of ultrafiltration and diuretics","volume":"58","author":"BJ Freda","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"ref3","article-title":"2016 ACC\/AHA\/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","author":"CW Yancy","year":"2016","journal-title":"2016 ACC\/AHA\/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.13R13CP","article-title":"Therapeutic potential of vasopressin-receptor antagonists in heart failure","volume":"124","author":"Y Izumi","year":"2014","journal-title":"Journal of pharmacological sciences"},{"issue":"16","key":"ref5","first-page":"e147","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"CW Yancy","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"ref6","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","author":"P Ponikowski","year":"2015","journal-title":"European heart journal"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11255-014-0855-2","article-title":"Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"I Nistor","year":"2015","journal-title":"International urology and nephrology"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10741-015-9503-x","article-title":"The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"20","author":"B Xiong","year":"2015","journal-title":"Heart failure reviews"},{"issue":"12","key":"ref9","first-page":"22117","article-title":"Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials","volume":"8","author":"C-J Yang","year":"2015","journal-title":"International journal of clinical and experimental medicine"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/FJC.0000000000000405","article-title":"Tolvaptan for Heart Failure, Systematic Review and Meta-Analysis of Trials","volume":"68","author":"E Alskaf","year":"2016","journal-title":"Journal of cardiovascular pharmacology"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"K Jujo","year":"2016","journal-title":"ESC Heart Failure"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction","volume":"22","author":"Y Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"ref13","first-page":"187","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2008"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7414","key":"ref15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"Bmj"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"A Chaimani","year":"2013","journal-title":"PloS one"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"S Dias","year":"2013","journal-title":"Med Decis Making"},{"issue":"16","key":"ref18","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"M Gheorghiade","year":"2004","journal-title":"JAMA"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"M Gheorghiade","year":"2007","journal-title":"JAMA"},{"issue":"21","key":"ref20","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"M Gheorghiade","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 1","key":"ref21","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s10557-011-6349-x","article-title":"Phase III clinical pharmacology study of tolvaptan","volume":"25","author":"T Inomata","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"MA Konstam","year":"2007","journal-title":"JAMA"},{"issue":"Suppl 1","key":"ref23","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","article-title":"Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"25","author":"M Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 1","key":"ref24","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"M Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 1","key":"ref25","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ihj.2015.07.006","article-title":"Effect of tolvaptan on acute heart failure with hyponatremia\u2014a randomized, double blind, controlled clinical trial","volume":"68","author":"E Shanmugam","year":"2016","journal-title":"Indian Heart J"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"JE Udelson","year":"2011","journal-title":"J Card Fail"},{"issue":"22","key":"ref27","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"JE Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"ref28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"JE Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2016.07.063","article-title":"Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction","volume":"221","author":"Y Matsue","year":"2016","journal-title":"Int J Cardiol"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11936-011-0149-2","article-title":"Update on the Management of Acute Decompensated Heart Failure","volume":"13","author":"DT Majure","year":"2011","journal-title":"Current Treatment Options in Cardiovascular Medicine"},{"issue":"19","key":"ref31","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","article-title":"Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study","volume":"111","author":"L Klein","year":"2005","journal-title":"Circulation"},{"issue":"Suppl 1","key":"ref32","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1111\/j.1751-7133.2010.00172.x","article-title":"Diuretic management in heart failure","volume":"16","author":"G Michael Felker","year":"2010","journal-title":"Congest Heart Fail"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/157488711795177895","article-title":"Tolvaptan: a new therapeutic agent","volume":"6","author":"G Aperis","year":"2011","journal-title":"Rev Recent Clin Trials"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0215624","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0184380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:57:28Z","timestamp":1588993048000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0184380"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,12]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0184380","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0215624","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,12]]}}}